Author: Carol White

Employers may be getting better at communicating about benefits during open enrollment.

A new California law could affect the design of life insurance-based long-term care (LTC) hybrid products.

Prescription drug companies and trade groups shelled out millions of dollars to lobby Congress as it considered legislation aimed at reining in skyrocketing drug prices, according to new lobbying disclosure reports.  The Pharmaceutical Research and Manufacturers of America (PhRMA) — the trade group representing branded drug companies — spent $6.2 million on lobbying in the third quarter of 2019, which ran from July through the end of September.

WASHINGTON — Democratic lawmakers in recent weeks have begun to advance an argument long seen as something of a third rail in U.S. politics: that slightly less biomedical innovation might be worth a dramatic reduction in drug prices. The surprising candor has come amid pushback to House Speaker Nancy Pelosi’s high-profile drug pricing bill, which the trade group PhRMA this month said represented “nuclear winter” for the development of new medicines.

Applied Underwriters executives have responded to efforts by the California Department of Insurance to halt the sale of one of its subsidiaries and threaten to upend a reported $920 million deal that’s been in the works for some time.

As U.S. officials press a massive case for alleged generic drug price fixing, authorities in the U.K. have unearthed an example of rivals working a little too closely with each other.